USPTO Art Unit 1654 Prosecution Statistics

Art Unit Information

Art Unit: 1654
Group: 1650
Tech Center: 1600
Total Cases: 12,861
Last Active: August 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19308016NOVEL COMPOUNDSAugust 2025October 2025Allow200NoNo
19219183DESMOPRESSIN ORAL COMPOSITIONSMay 2025November 2025Allow610NoNo
19199523KITS FOR PREPARING AND DELIVERING PURIFIED CORTICOTROPINMay 2025September 2025Allow410NoNo
19197254Vaccines against Chlamydia sp.May 2025March 2026Allow1021YesNo
19193303Skin Care Compositions and Methods of Using the SameApril 2025September 2025Allow411YesNo
19098553METHOD OF USING A GIP/GLP1 CO-AGONIST FOR DIABETESApril 2025August 2025Allow410YesNo
19085432COLLAGEN PEPTIDE-BASED MEDICAMENT COMPOSITIONS AND DEVICES AND METHODS OF PRODUCTION AND USE THEREOFMarch 2025October 2025Allow710YesNo
19071109COMPOSITIONS OF GLP-1 PEPTIDES AND PREPARATION THEREOFMarch 2025December 2025Allow920NoNo
19070846Compositions and Methods for Treating Neurodegenerative Diseases and DisordersMarch 2025January 2026Abandon1120NoNo
19070810Compositions and Methods for Treating Cardiovascular Diseases and DisordersMarch 2025February 2026Abandon1120NoNo
19054696DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODSFebruary 2025September 2025Allow720YesNo
19052262Insulin DerivativeFebruary 2025December 2025Abandon1001NoNo
19042887GIP/GLP1 AGONIST COMPOSITIONSJanuary 2025May 2025Allow400YesNo
18993517A PHARMACEUTICAL COMPOSITION PROVIDING MUCOLYTIC EFFECTJanuary 2025October 2025Allow910YesNo
19005623COMPOSITIONS COMPRISING PEMVIDUTIDE AND AN ACYLATED AMINO ACIDDecember 2024October 2025Allow911YesNo
18980129Compositions and Methods for Treating Endocrine Diseases and DisordersDecember 2024March 2025Allow310NoNo
18955504DESMOPRESSIN ORAL COMPOSITIONSNovember 2024May 2025Allow610YesNo
18949272FUSION PROTEINS FOR THE TREATMENT OF CARDIOMETABOLIC DISEASESNovember 2024June 2025Allow721NoNo
18926573Methods and Compositions for Delivery of Biotin to MitochondriaOctober 2024October 2025Allow1220YesNo
18905498KITS FOR PREPARING AND DELIVERING PURIFIED CORTICOTROPINOctober 2024April 2025Allow710NoNo
18896310STABLE LIQUID COMPOSITIONS OF GLUCAGONSeptember 2024November 2025Abandon1320NoNo
18892760Compositions and Methods for Treating Endocrine Diseases and DisordersSeptember 2024January 2026Abandon1640NoNo
18883317LONG-ACTING AMYLIN RECEPTOR AGONISTS AND USES THEREOFSeptember 2024October 2025Allow1300YesNo
18829566CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRASSeptember 2024November 2024Allow200YesNo
18824970POLYPEPTIDE WITH ANTI-MYCOBACTERIUM TUBERCULOSIS ACTIVITY, AND PREPARATION METHOD AND USE THEREOFSeptember 2024March 2025Allow611YesNo
18824445Formulations of MANP and Uses ThereofSeptember 2024August 2025Allow1121YesNo
18821027AQUEOUS SOLUTION COMPRISING A GLUTATHIONE SALTAugust 2024May 2025Allow820NoNo
18818974METHODS FOR STORING AND WARMING PURIFIED CORTICOTROPIN COMPOSITIONSAugust 2024December 2024Allow310NoNo
18800436PROCESS FOR PREPARING A GIP/GLP1 DUAL AGONISTAugust 2024January 2026Allow1731YesNo
18800392PROCESS FOR PREPARING A GIP/GLP1 DUAL AGONISTAugust 2024January 2026Abandon1730NoNo
18778554PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOFJuly 2024December 2024Allow510YesNo
18773066CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTIONJuly 2024December 2024Allow501YesNo
18756500NOVEL CXCR4-TARGETING COMPOUNDSJune 2024August 2025Allow1311YesNo
18720420METHOD FOR OPTIMIZING VIRUS MEMBRANE FUSION INHIBITOR, BROAD-SPECTRUM ANTI-CORONAVIRUS LIPOPEPTIDE AND USE THEREOFJune 2024August 2025Allow1421NoNo
18742691BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR CD137June 2024January 2026Allow1911YesNo
18741178USE OF p55-GAMMA GENE AND/OR p55-GAMMA PROTEIN AS TARGET IN MAINTAINING CARDIAC IRON HOMEOSTASIS AND TREATING RELATED DISEASEJune 2024January 2026Abandon2021NoNo
18734628PREPARATION AND APPLICATION OF SUPRAMOLECULAR SELF-ASSEMBLED HYALURONIC ACID HYDROGELJune 2024December 2025Abandon1811NoNo
18733576ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAMEJune 2024September 2024Allow310NoNo
18731133COMPOSITIONS AND METHOD FOR TREATING ACUTE RADIATION SYNDROMEMay 2024June 2025Allow1310NoNo
18674657POLYPEPTIDES HAVING ANTI-SENESCENT EFFECTS AND USES THEREOFMay 2024January 2025Allow811YesNo
18670946Methods and Compositions to Assist and Support the Formation of Red Blood Cells and HemoglobinMay 2024November 2024Allow610YesNo
18667958POLYPEPTIDE-COUPLED SMALL MOLECULE COMPOUND AND ANTIVIRAL APPLICATION THEREOFMay 2024December 2024Allow711YesNo
18664876LACTIPLANTIBACILLUS PLANTARUM FOR DEGRADING TANNINS AND SAPONINS, AND USE THEREOFMay 2024July 2025Allow1421NoNo
18654900PHARMACEUTICAL COMPOSITIONS COMPRISING TEIXOBACTINMay 2024December 2025Allow1911YesNo
18647078PHARMACEUTICAL COMPOSITION COMPRISING A GLP-1 AGONIST, AN INSULIN AND METHIONINEApril 2024March 2026Abandon2210NoNo
18640964AQUEOUS SOLUTION COMPRISING A GLUTATHIONE SALTApril 2024May 2024Allow100YesNo
18640840Methods and Compositions for Treatment of Angiogenic Disorders Using Anti-VEGF AgentsApril 2024September 2025Allow1720NoNo
18640722IMMUNOREGULATORY MOLECULES AND USES THEREFORApril 2024June 2025Abandon1401NoNo
18634717METHODS FOR STORING AND WARMING PURIFIED CORTICOTROPIN COMPOSITIONSApril 2024August 2024Allow410YesNo
18626956CNP CYCLIC PEPTIDE, AND MEDICINE, EXTERNAL PREPARATION AND COSMETIC EACH CONTAINING SAID CYCLIC PEPTIDEApril 2024October 2025Abandon1801NoNo
18625923DESMOPRESSIN ORAL COMPOSITIONSApril 2024October 2024Allow3811YesNo
18621336COMPOSITIONS FOR TREATING MACULAR EDEMAMarch 2024July 2025Abandon1511YesNo
18618780GLUCOSE-RESPONSIVE INSULIN ANALOGS AND METHODS OF USE THEREOFMarch 2024October 2025Abandon1920NoNo
18615150Compositions and Methods for Treating Endocrine Diseases and DisordersMarch 2024August 2024Allow501NoNo
18605381PHARMACEUTICAL PREPARATIONMarch 2024August 2025Allow1820YesNo
18604387NUCLEASE-DENDRIMER FORMULATIONS FOR COVID-19 AND BROAD-SPECTRUM ANTIVIRAL THERAPY AND PROPHYLAXISMarch 2024October 2025Allow1901NoNo
18604400CLEAVABLE RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOFMarch 2024November 2024Allow811NoNo
18603127METHODS OF USING GLYCOPOLYSIALYLATED THERAPEUTIC PROTEINSMarch 2024January 2026Abandon2211NoNo
18602421PHOTOSTABILIZED COMPOSITIONS AND A METHOD FOR STABILIZING PHOTOSENSITIVE COMPONENTSMarch 2024February 2026Allow2421YesNo
18600557COMPOSITIONS AND METHODS FOR TREATMENT OF WOUNDS AND INFLAMMATORY SKIN CONDITIONSMarch 2024June 2025Allow1631YesNo
18598878GLYCOPROTEINS HAVING LIPID MOBILIZING PROPERTIES AND THERAPEUTIC USES THEREOFMarch 2024September 2025Abandon1902NoNo
18598719IMMUNE CHECKPOINT INHIBITOR COMBINATIONSMarch 2024January 2025Allow1010NoNo
18595656METHODS OF TREATING OR PREVENTING STENT THROMBOSISMarch 2024May 2025Abandon1410NoNo
18594290SKIN CARE PRODUCT WITH PROTEIN MATRIXMarch 2024October 2025Allow2011YesNo
18444443COMPOSITIONS COMPRISING PHARMACEUTICALLY ACCEPTABLE SALTS OF GLUCAGON-LIKE PEPTIDE-1 ANALOGS AND USES THEREOFFebruary 2024December 2024Allow1010NoNo
18439088FORMULATIONS FOR INTRAOCULAR DELIVERY OF PEPTIDES DERIVED FROM TYPE IV COLLAGENFebruary 2024May 2025Abandon1520YesNo
18436355SCAFFOLD PROTEINSFebruary 2024December 2024Allow1001NoNo
18431596FIBROIN-DERIVED PROTEIN COMPOSITIONFebruary 2024March 2025Allow1310NoNo
18427414BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NECTIN-4January 2024January 2026Allow2410YesNo
18422307METHODS FOR REGULATING FREE FATTY ACID FLUX USING FAT SPECIFIC PROTEIN 27 (FSP27) COMPOSITIONSJanuary 2024April 2025Abandon1511NoNo
18422177GIP/GLP1 AGONIST COMPOSITIONSJanuary 2024July 2025Allow1700YesNo
18419845SMALL PEPTIDE COMPOSITIONS AND USES THEREOFJanuary 2024June 2025Allow1701YesNo
18420397TREATMENT OF HEART DISEASE BY DISRUPTION OF THE ANCHORING OF PP2AJanuary 2024May 2025Abandon1611NoNo
18420177Atomic Description of Immune Complex that Causes Heparin-Induced ThrombocytopeniaJanuary 2024December 2024Allow1110NoNo
18420098Formulation and Method of Preparing Glucagon-like Peptide-1 (GLP-1) for Oral AdministrationJanuary 2024August 2025Abandon1930NoNo
18417206METHODS OF TREATING ALZHEIMERS DISEASEJanuary 2024March 2025Allow1410NoNo
18416017EXPRESSION AND PURIFICATION OF CAS ENZYMESJanuary 2024December 2025Abandon2210NoNo
18414690COMBINATIONAL THERAPY OF LSD1 INHIBITORS WITH P21 ACTIVATORS IN THE TREATMENT OF CANCERJanuary 2024November 2025Allow2230YesNo
18413260TREATMENT FOR DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH AN ORAL ANTIDIABETIC DRUGJanuary 2024April 2025Abandon1410NoNo
18412585NOVEL PTH MIMETIC PEPTIDE BASED ON PROTEIN DOMAIN RECONSTRUCTION AND APPLICATION THEREOFJanuary 2024May 2025Allow1610YesNo
18408052ACYLATED GLUCAGON ANALOGUESJanuary 2024July 2025Allow1810NoNo
18407324CNP PRODRUGS WITH LARGE CARRIER MOIETIESJanuary 2024March 2025Abandon1410NoNo
18402297PLANT MESSENGER PACKS ENCAPSULATING POLYPEPTIDES AND USES THEREOFJanuary 2024February 2026Abandon2501NoNo
18402138BIOACTIVE POLYMERIC DRESSING FOR ACCELERATED WOUND CLOSUREJanuary 2024November 2024Allow1110NoNo
18400012MILBEMYCIN STRAIN WITH HIGH-YIELD AND ITS APPLICATIONDecember 2023July 2025Allow1920YesNo
18393925METHODS OF SCAR PREVENTION AND/OR TREATMENTDecember 2023October 2025Abandon2221NoNo
18394401INSULIN LIKE GROWTH FACTOR BINDING PROTEIN BIOACTIVE PEPTIDE FRAGMENTSDecember 2023May 2025Allow1711NoNo
18392459STABLE ASCORBIC ACID COMPOSITIONS AND METHODS OF USING SAMEDecember 2023February 2025Allow1410NoNo
18392545DOSING REGIMENSDecember 2023November 2025Allow2341YesNo
18545302VARIANT OF A BPIFB4 PROTEINDecember 2023August 2025Allow2010YesNo
18541847COMPOUNDS FOR USE IN INDUCING MYOCARDIAL PERFUSION RECOVERYDecember 2023February 2026Abandon2611NoNo
18537886SIRPalpha-41BBL FUSION PROTEIN AND METHODS OF USE THEREOFDecember 2023February 2025Allow1411YesNo
18534620ATF5 Peptide Variants and Uses ThereofDecember 2023September 2024Allow1001NoNo
18528195POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSEDecember 2023May 2025Abandon1810NoNo
18527006ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASESDecember 2023April 2025Allow1611YesNo
18524472ANALOGUES OF PYYNovember 2023January 2025Allow1440YesNo
18522766METHODS OF MODULATING ALKNovember 2023January 2025Abandon1401NoNo
18520428ODORANT-BINDING PROTEIN COMPOSITIONS, METHODS AND USES THEREOFNovember 2023October 2024Allow1121YesNo
18518879COLLAGEN COMPOSITIONS AND USES FOR BIOMATERIAL IMPLANTSNovember 2023January 2025Abandon1401NoNo
18518880COLLAGEN COMPOSITIONS AND USES FOR BIOMATERIAL IMPLANTSNovember 2023January 2025Abandon1401NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1654.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
100
Examiner Affirmed
65
(65.0%)
Examiner Reversed
35
(35.0%)
Reversal Percentile
63.5%
Higher than average

What This Means

With a 35.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
1056
Allowed After Appeal Filing
268
(25.4%)
Not Allowed After Appeal Filing
788
(74.6%)
Filing Benefit Percentile
17.3%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 25.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Art Unit 1654 - Prosecution Statistics Summary

Executive Summary

Art Unit 1654 is part of Group 1650 in Technology Center 1600. This art unit has examined 12,861 patent applications in our dataset, with an overall allowance rate of 59.0%. Applications typically reach final disposition in approximately 32 months.

Comparative Analysis

Art Unit 1654's allowance rate of 59.0% places it in the 14% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.

Prosecution Patterns

Applications in Art Unit 1654 receive an average of 1.74 office actions before reaching final disposition (in the 37% percentile). The median prosecution time is 32 months (in the 40% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With fewer office actions than average, plan for relatively streamlined prosecution.
  • The median prosecution time is longer than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.